Matthew J Cotter Selected Research

Matthew J Cotter Research Topics

6	Neoplasms (Cancer) 09/2021 - 02/2008
3	Breast Neoplasms (Breast Cancer) 01/2022 - 12/2018
2	Sarcoma (Soft Tissue Sarcoma) 02/2012 - 03/2010
1	Hematologic Neoplasms (Hematological Malignancy) 09/2021
1	Disease Progression 12/2018
1	Renal Cell Carcinoma (Grawitz Tumor) 03/2010
1	Lewis Lung Carcinoma 03/2010
1	Thymoma (Thymic Carcinoma) 03/2010
1	Carcinoma (Carcinomatosis) 03/2010
1	Pancreatic Neoplasms (Pancreatic Cancer) 03/2010
1	Adenoviridae Infections (Adenovirus Infections) 06/2009
1	Neutropenia 01/2009
1	Multiple Myeloma 02/2008
1	Inflammation (Inflammations) 06/2004
1	Vasculitis (Vasculitides) 02/2003
1	Traumatic Shock 02/2003
1	Disseminated Intravascular Coagulation 02/2003

3	palbociclibIBA 01/2022 - 12/2018
3	Hormones (Hormone)IBA 01/2022 - 12/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2019
2	Letrozole (Femara)FDA LinkGeneric 10/2019 - 12/2018
2	AntibodiesIBA 01/2009 - 02/2003
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2009 - 02/2003
1	talazoparibIBA 09/2021
1	human ERBB2 proteinIBA 12/2018
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 12/2018
1	AntigensIBA 10/2010
1	bardoxolone methylIBA 03/2010
1	AcidsIBA 03/2010
1	EstersIBA 03/2010
1	TriterpenesIBA 03/2010
1	Gemcitabine FDA Link 03/2010
1	Antiviral Agents (Antivirals)IBA 06/2009
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 05/2009
1	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2009
1	Complement System Proteins (Complement)IBA 01/2009
1	CalnexinIBA 02/2008
1	DNA (Deoxyribonucleic Acid)IBA 06/2004
1	Dacarbazine (DIC)FDA LinkGeneric 02/2003